Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral ONC201 in Relapsed/Refractory Multiple Myeloma
NCT02863991Phase 2Terminated
- Sponsor
- Chimerix Inc.
- Start
- Apr 2017
- Primary completion
- Sep 2019
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dordaviprone in multiple myeloma (MM), sponsored by Chimerix Inc.. Started Apr 2017; status: terminated.
02
Drugs
dordaviprone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02863991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02863991.